Related Experiment Video
Updated: Jul 28, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[New studies of COX-inhibitors, yet issues remain]
1Reumatologiska kliniken, Universitetssjukhuset i Lund. Frank.Wollheim@reum.lu.se
Abstract:
Advantages and risks related to the use of selective COX-2 inhibitors when treating arthritis are currently being scrutinized by authorities and public. The discussion tends towards exaggerated claims for or against their usefulness. The issue of cardiovascular safety is still not finally settled. In an experimental study using patients with severe coronary disease, administration of celecoxib resulted in improved endothelial function together with reduced CRP levels. Gastrointestinal tolerance was studied in patients who had recently recovered from peptic ulcer bleeding. In this group of high risk patients, celecoxib was as safe as combined therapy using omeprazol and diclofenac when given for 6 months. However, both COX inhibitors caused hypertension and adverse renal effects. The second generation of selective inhibitors is being launched. Etoricoxib--related to rofecoxib--was shown to be as potent as indomethacin in the treatment of acute gout, but it caused fewer adverse reactions. In general, however, any advantage of second generation as compared to first generation COX-2 inhibitors remains to be proven. The Swedish Council on Technology Assessment in Health Care, in its "SBU Alert", has published an appraisal of celecoxib and rofecoxib, in which the need for further long-term safety studies is emphasized.
Insights
Selective COX-2 inhibitors show mixed results in arthritis treatment. While some improve cardiovascular markers and gastrointestinal safety, they carry risks of hypertension and renal issues, necessitating further long-term studies.
Area of Science:
- Pharmacology
- Rheumatology
- Cardiology
Background:
- Selective COX-2 inhibitors are under scrutiny for arthritis treatment due to debated cardiovascular safety.
- Existing research presents conflicting data on their efficacy and risks.
Purpose of the Study:
- To evaluate the cardiovascular and gastrointestinal safety of selective COX-2 inhibitors.
- To compare the efficacy and adverse effects of first and second-generation COX-2 inhibitors.
Main Methods:
- Experimental study on patients with severe coronary disease.
- Gastrointestinal tolerance assessment in high-risk patients post-peptic ulcer bleeding.
- Comparison of etoricoxib with indomethacin for acute gout treatment.
Main Results:
- Celecoxib improved endothelial function and reduced CRP levels in patients with coronary disease.
- Celecoxib demonstrated comparable gastrointestinal safety to omeprazole and diclofenac in high-risk patients over 6 months.
- Both COX inhibitors induced hypertension and adverse renal effects. Etoricoxib showed comparable efficacy to indomethacin for gout with fewer adverse reactions.
Conclusions:
- Selective COX-2 inhibitors present a complex risk-benefit profile, with potential cardiovascular and renal adverse effects.
- Further long-term safety studies are essential, particularly for second-generation inhibitors, to establish clear advantages over first-generation agents.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:30Acute Coronary Syndrome III: Diagnostic Studies